Rate of cyp51A mutation in Aspergillus fumigatus among lung transplant recipients with targeted prophylaxis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1064-1067

  Shalhoub, S ^a   Luong, M L ^a   Howard, S J ^b   Richardson, S ^a,c   Singer, L G ^a   Chaparro, C ^a   Keshavjee, S ^a   Akinlolu, Y ^a   Rotstein, C ^a   Mazzulli, T ^a,c   Husain, S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Antifungal; Resistance; Transplantation

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; CYTOCHROME P-450 CYP51A, ASPERGILLUS; CYTOCHROME P450; FUNGAL PROTEIN;

ANTIFUNGAL PROPHYLAXIS; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; CHRONOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYP51A GENE; DRUG EXPOSURE; FUNGAL COLONIZATION; FUNGAL GENE; FUNGUS ISOLATION; FUNGUS MUTANT; GRAFT RECIPIENT; HUMAN; LUNG ASPERGILLOSIS; LUNG TRANSPLANTATION; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; PROPHYLAXIS; PROSPECTIVE STUDY; WILD TYPE; CHEMOPROPHYLAXIS; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROCEDURES;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CHEMOPREVENTION; CYTOCHROME P-450 ENZYME SYSTEM; FUNGAL PROTEINS; HUMANS; LUNG TRANSPLANTATION; MUTATION RATE; PROSPECTIVE STUDIES; PULMONARY ASPERGILLOSIS; TRANSPLANT RECIPIENTS; VORICONAZOLE;

EID: 84926452001     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku528     Document Type: Article

References (20)

1. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-11.
2. Warris A, Weemaes CM, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med 2002; 347: 2173-4.
3. Alanio A, Cabaret O, Sitterle E et al. Azole preexposure affects the Aspergillus fumigatus population in patients. Antimicrob Agents Chemother 2012; 56: 4948-50.
4. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. Substitutions at methionine 220 in the 14a-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004; 48: 2747-50.
5. Denning DW, Park S, Lass-Florl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 1123-9.
6. Alanio A, Sitterle E, LianceM et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66: 371-4.
7. Lockhart SR, Frade JP, Etienne KA et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55: 4465-8.
8. Baddley JW, Marr KA, Andes DR et al. Patterns of susceptibility of spergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3271-5.
9. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
10. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
11. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
12. Clinical and Laboratory Standards Institute. Reference Method for Broth Microdilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
13. Bader O, Weig M, Reichard U et al. cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother 2013; 57: 3513-7.
14. Badali H, Vaezi A, Haghani I et al. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses 2013; 56: 659-63.
15. Camps SM, van der Linden JW, Li Y et al. Rapid induction of multiple resistance mechanism in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012; 56: 10-6.
16. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52: 2468-72.
17. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M et al. A point mutation in the 14a-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47: 1120-4.
18. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51: 1897-904.
19. HopeWW, Cuenca-Estrella M, Lass-Florl C et al. EUCAST technical note on voriconazole and Aspergillus spp. Clin Microbiol Infect 2013; 19: E278-80.
20. Mavridou E, Meletiadis J, Jancura P et al. Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. PLoS One 2013; 8: e72280.